PET Scan of Brain Metabolism in Relation to Age and Disease

Launched by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS) · Jan 18, 2000

Keywords

ClinConnect Summary

The Brain Physiology and Metabolism Section (BPMS) of the National Institute on Aging (NIA) and the Clinical Neuroscience Program (CNP) of the National Institute of Neurological Disorders and Stroke (NINDS) propose to study regional brain phospholipid metabolism in young and old normal volunteers and in patients with Alzheimer disease. The method to be employed, developed from animal studies, involves the intravenous injection of a radiolabeled polyunsaturated fatty acid, \[11C\]arachidonic acid and measuring regional brain radioactivity using positron emission tomography (PET). A mathemati...

Gender

ALL

Eligibility criteria

• NORMAL VOLUNTEERS:
• • Age between 18 and 90 years.
• • No past or current medical condition that would interfere with brain function.
• • No history of alcoholism, psychiatric or neurological illness, head trauma with loss of consciousness, history of exposure to central nervous system toxin; history of central nervous system infection, metabolic, endocrine, connective tissue disease; hypertension or other cardiovascular disorder; abnormal renal, liver or pulmonary function; blood or coagulation disease; malignancy; psychopharmacological treatment; neurodegenerative or neurodevelopmental disorder; stroke; epilepsy; subjects requiring regular medication, and subjects demonstrated by drug screening to have taken a controlled substance.
• • No occupational exposure to metal slivers or shavings.
• • No females who are pregnant or breast feeding.
• PATIENTS WITH ALZHEIMER DISEASE:
• • Age between 18 and 90 years.
• • Diagnosis of possible or probably Alzheimer Disease according to NINCDS-ADRDA criteria.
• • Aside from Alzheimer Disease, no past or current medical condition that would interfere with brain function.
• • No history of alcoholism, psychiatric or neurological illness, head trauma with loss of consciousness, history of exposure to central nervous system toxin; history of central nervous system infection, metabolic, endocrine, connective tissue diseases; hypertension or other cardiovascular disorder; abnormal renal, liver or pulmonary function; blood or coagulation disease; malignancy; psychopharmacological treatment.
• • No females who are pregnant or breast feeding.